DUBLIN – Crispr Therapeutics AG pulled in $56 million in an IPO on Nasdaq, alongside a concurrent private placement with strategic partner Bayer AG, which raised another $35 million. The combined transactions take the company’s total funding raised from inception to $384.4 million, including private and public equity investment, convertible loans and collaboration revenues.